We apply our computational methods in the earliest phase of drug discovery. We replace most of the experimental methods, which makes the discovery process much quicker, much cheaper and the outcomes more accurate. We achieve 50-100x higher hit rates than HTS. We work with a minimum of experimental lab work and therefore are >5x quicker and save up to 80% of costs
This means we clarify druggability and mode of action at the earliest possible time and then follow through a structured and very disciplined process until we have patentable compound series. We achieve > 20-fold productivity gains in target druggability evaluation.
We discover and design small molecules which act as inhibitors of disease targets. The drug candidates we discover and design come with an accuracy that increases their potential for success in the later development stages.We apply this for our own product development but also to help others in their discovery work.
Our MFMD technology is predestined to explore protein surfaces, protein-protein interactions and binding sites which are difficult to detect or to drug.
We develop tailor-made solutions by combining our unique technology with our structured and disciplined process management. Our scientific advisory competence enables us to find the right solution for the problem at hand and not just a solution.
We aim to build our product pipeline in the growing field of Protein-Protein Interaction Inhibitors, Ion-Channels and with designed small molecules to replace therapeutic proteins.